Holen Sie sich die Stockscreener-App
1.67
11.17%
-0.21
Vorhandelsmarkt:
1.62
-0.05
-2.99%
Schlusskurs vom Vortag:
$1.88
Offen:
$1.88
24-Stunden-Volumen:
443.41K
Relative Volume:
0.13
Marktkapitalisierung:
$12.81M
Einnahmen:
$598.00K
Nettoeinkommen (Verlust:
$-44.93M
KGV:
-0.201
EPS:
-8.31
Netto-Cashflow:
$-17.32M
1W Leistung:
+40.34%
1M Leistung:
+39.75%
6M Leistung:
-45.02%
1J Leistung:
-89.29%
1-Tages-Spanne:
$1.63
$1.89
1-Wochen-Bereich:
$1.20
$2.8599
52-Wochen-Spanne:
$1.09
$18.00
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Ernexa Therapeutics Inc
Sektor
Branche
Telefon
(617) 798-6700
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Vergleichen Sie ERNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
1.67 | 14.42M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Should I hold or sell Ernexa Therapeutics Inc. stock in 2025Risk Management & High Conviction Trade Alerts - newser.com
Is it too late to sell Ernexa Therapeutics Inc.Portfolio Risk Summary & High Yield Equity Trading Tips - newser.com
Multi asset correlation models including Ernexa Therapeutics Inc.Market Movers & AI Optimized Trading Strategy Guides - newser.com
Will Ernexa Therapeutics Inc. bounce back from current support2025 EndofYear Setup & Free High Return Stock Watch Alerts - newser.com
Will breakout in Ernexa Therapeutics Inc. lead to full recoveryProduct Launch & Reliable Entry Point Alerts - newser.com
Why Ernexa Therapeutics Inc. stock is recommended by analystsLayoff News & Scalable Portfolio Growth Methods - newser.com
Risk vs reward if holding onto Ernexa Therapeutics Inc.Portfolio Growth Summary & Fast Gaining Stock Reports - newser.com
How strong is Ernexa Therapeutics Inc. stock revenue growthJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - newser.com
How Ernexa Therapeutics Inc. stock reacts to oil pricesJuly 2025 Outlook & Long Hold Capital Preservation Plans - newser.com
Sector ETF performance correlation with Ernexa Therapeutics Inc.Trade Entry Summary & Precise Buy Zone Identification - newser.com
Using data filters to optimize entry into Ernexa Therapeutics Inc.Weekly Trend Recap & Expert Curated Trade Setup Alerts - newser.com
Analyzing drawdowns of Ernexa Therapeutics Inc. with statistical toolsEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Is Ernexa Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
How to monitor Ernexa Therapeutics Inc. with trend dashboards2025 Year in Review & Stock Portfolio Risk Control - newser.com
Will Ernexa Therapeutics Inc. stock benefit from automationTrade Analysis Report & Fast Gain Stock Trading Tips - newser.com
Is Ernexa Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
3 Penny Stocks to Watch Now, 10/30/25 - TipRanks
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last? - ts2.tech
ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials - Asianet Newsable
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer - PR Newswire
/C O R R E C T I O N -- Cellipont Bioservices/ - Lelezard
Ernexa Therapeutics Soars: Innovation’s Role Debated - StocksToTrade
Ernexa Therapeutics stock soars after Cellipont manufacturing deal By Investing.com - Investing.com Philippines
Ernexa Therapeutics stock soars after Cellipont manufacturing deal - Investing.com
Cellipont Bioservices and Ernexa Therapeutics enter cell therapy manufacturing partnership to advance ERNA-101 toward clinical trials in ovarian cancer - MarketScreener
Finanzdaten der Ernexa Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):